We have located links that may give you full text access.
Angiographic and clinical performance of a paclitaxel coated balloon compared to a 2nd generation sirolimus eluting stent in patients with in-stent restenosis- the BIOLUX randomized controlled trial.
EuroIntervention 2018 May 30
AIMS: The optimal treatment of in-stent restenosis (ISR) remains unknown. This study evaluates the efficacy and safety of a paclitaxel coated balloon compared to a 2nd generation sirolimus eluting stent in patients with ISR in bare metal stents (BMS) or drug eluting stents (DES).
METHODS AND RESULTS: A total of 229 patients with ISR from 13 German centers and one Latvian center were 2:1 randomly allocated to DCB (n=157) or DES (n=72). The primary efficacy endpoint was defined as late lumen loss (LLL) at 6 month, and the primary safety endpoint was target lesion failure (TLF) at 12 months. LLL in the DCB arm was 0.03 ± 0.40mm compared to 0.20 ± 0.70mm in the DES arm (p=0.40). DCB proved non-inferior to DES (Δ = -0.17 ±0.52mm (97.5% CI [-∞;-0.01]); p < 0.0001). At 12 months primary safety endpoint rates were 16.7% in the DCB arm and 14.2% in the DES arm (p=0.65). TLF rates remained similar at 18 months (DCB versus DES; 19.5% versus 18.6%, p=0.88).
CONCLUSIONS: In patients with DES or BMS ISR, paclitaxel coated balloon treatment showed similar LLL at 6 months and TLF rates up to 18 months compared to 2nd generation sirolimus eluting stents.
METHODS AND RESULTS: A total of 229 patients with ISR from 13 German centers and one Latvian center were 2:1 randomly allocated to DCB (n=157) or DES (n=72). The primary efficacy endpoint was defined as late lumen loss (LLL) at 6 month, and the primary safety endpoint was target lesion failure (TLF) at 12 months. LLL in the DCB arm was 0.03 ± 0.40mm compared to 0.20 ± 0.70mm in the DES arm (p=0.40). DCB proved non-inferior to DES (Δ = -0.17 ±0.52mm (97.5% CI [-∞;-0.01]); p < 0.0001). At 12 months primary safety endpoint rates were 16.7% in the DCB arm and 14.2% in the DES arm (p=0.65). TLF rates remained similar at 18 months (DCB versus DES; 19.5% versus 18.6%, p=0.88).
CONCLUSIONS: In patients with DES or BMS ISR, paclitaxel coated balloon treatment showed similar LLL at 6 months and TLF rates up to 18 months compared to 2nd generation sirolimus eluting stents.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Management of Diverticulitis: A Review.JAMA Surgery 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app